UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Journal of clinical oncology, 2018-02, Vol.36 (4), p.359-366

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

Cancer, 2015-07, Vol.121 (13), p.2193-2197

2015

Link zum Volltext

Verfügbarkeit prüfen

Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

Clinical and molecular hepatology, 2014-06, Vol.20 (2), p.218-222

2014

Link zum Volltext

Verfügbarkeit prüfen

Role of Primary Tumor Resection Among Chemotherapy-Treated Patients with Synchronous Stage IV Colorectal Cancer: A Survival Analysis

Journal of gastrointestinal surgery, 2014-03, Vol.18 (3), p.592-598

2014

Link zum Volltext

Verfügbarkeit prüfen

Current Options for Third-Line Treatment of Metastatic Colorectal Cancer

Clinical advances in hematology & oncology, 2016-03, Vol.14 (3 Suppl 3), p.1-15

2016

Link zum Volltext

Verfügbarkeit prüfen

Mortality Risk After Preoperative Versus Postoperative Chemotherapy and Radiotherapy in Lymph Node-Positive Rectal Cancer

Journal of gastrointestinal surgery, 2013-02, Vol.17 (2), p.374-381

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT120: Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT120-CT120

2015

Link zum Volltext

Verfügbarkeit prüfen

Liver Imaging : Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

Clinical and molecular hepatology, 2014-06, Vol.20 (2), p.218

2014

Link zum Volltext

Verfügbarkeit prüfen

The Prevalence of Second Malignancies and Autoimmune Diseases in Patients with Lymphoproliferative Disorders

Blood, 2006-11, Vol.108 (11), p.4608-4608

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Journal of clinical oncology, 2019-05, Vol.37 (13), p.1062-1069

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT066: Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT066-CT066

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.208-208

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 13 von 13

Suche als RSS-Feed

Aktive Filter

ThemaCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(13)

Sprache

Englisch
(12)
Koreanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Journal Of Clinical Oncology
(3)
Cancer Research
(2)
Clinical And Molecular Hepatology
(2)
Journal Of Gastrointestinal Surgery
(2)
Blood
(1)
Cancer
(1)
Clinical Advances In Hematology & Oncology
(1)
Jama Oncology
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

Role of Primary Tumor Resection Among Chemotherapy-Treated Patients with Synchronous Stage IV Colorectal Cancer: A Survival Analysis

Current Options for Third-Line Treatment of Metastatic Colorectal Cancer

Mortality Risk After Preoperative Versus Postoperative Chemotherapy and Radiotherapy in Lymph Node-Positive Rectal Cancer

Abstract CT120: Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer

Liver Imaging : Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

The Prevalence of Second Malignancies and Autoimmune Diseases in Patients with Lymphoproliferative Disorders

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Abstract CT066: Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma

A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139)

Aktive Filter

Suchergebnisse filtern